LongevityHuman RCT
SS-31 (elamipretide): what a decade of human trials found
Elamipretide is now an FDA-approved drug for one ultra-rare disease, on the strength of 12 patients. Its large trials in commoner conditions mostly missed their main goals.
SS-31
A mitochondria-targeted tetrapeptide with several human trials; FDA-approved only for Barth syndrome, after most other trials missed their main goals.
- Also known as
- Elamipretide, Forzinity, MTP-131, Bendavia
- Area
- Longevity
- Status
- US: FDA accelerated approval for Barth syndrome only (Sept 2025); not approved otherwise